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ABSTRACT
Background: Neuroblastoma is an aggressive childhood malignancy of the 
sympathetic nervous system. Despite multi-modal therapy, survival of high-risk 
patients remains disappointingly low, underscoring the need for novel treatment 
strategies. The discovery of ALK activating mutations opened the way to precision 
treatment in a subset of these patients. Previously, we investigated the transcriptional 
effects of pharmacological ALK inhibition on neuroblastoma cell lines, six hours after 
TAE684 administration, resulting in the 77-gene ALK signature, which was shown to 
gradually decrease from 120 minutes after TAE684 treatment, to gain deeper insight 
into the molecular effects of oncogenic ALK signaling.
Aim: Here, we further dissected the transcriptional dynamic profiles of 
neuroblastoma cells upon TAE684 treatment in a detailed timeframe of ten minutes 
up to six hours after inhibition, in order to identify additional early targets for 
combination treatment.
Results: We observed an unexpected initial upregulation of positively regulated 
MYCN target genes following subsequent downregulation of overall MYCN activity. 
In addition, we identified adrenomedullin (ADM), previously shown to be implicated 
in sunitinib resistance, as the earliest response gene upon ALK inhibition.
Conclusions: We describe the early and late effects of ALK inhibitor TAE684 
treatment on the neuroblastoma transcriptome. The observed unexpected 
upregulation of ADM warrants further investigation in relation to putative ALK 
resistance in neuroblastoma patients currently undergoing ALK inhibitor treatment.
INTRODUCTION
Neuroblastoma (NB) is a childhood cancer arising 
from malignant transformation of cells from the sympatho-
adrenergic lineage of the developing neural crest [1] and is 
characterized by a large clinical heterogeneity, including 
patients with tumours that spontaneously regress as well 
as patients with metastasis and refractory disease despite 
intensive therapy regimens [2]. For these high-risk 
neuroblastoma cases, a better understanding of the genes 
and pathways that are involved in disease development 
and progression is currently fuelling the identification of 
new molecular targets for therapy [3]. 
Overall, given the low frequency of mutations in 
neuroblastoma, options for targeted therapy are relatively 
limited. However, the recurrent somatic mutations of 
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the tyrosine kinase receptor ALK identified in 8-10% of 
primary neuroblastoma tumours [4–8] and the emergence 
of ALK mutations at relapse mark ALK as an important 
novel drug target [9, 10]. Several orally available small 
molecule ALK inhibitors have been developed and 
successfully applied in patients with other ALK mutant 
tumour entities, so-called ALKoma’s, most notably a 
subset of lung cancers [11–17]. Several of these small 
molecule ALK inhibitors have recently gone into phase 1 
clinical trials for patients with refractory neuroblastoma, 
inflammatory myofibroblastic tumour, non-small-cell 
lung cancer (NSCLC) and anaplastic large-cell lymphoma 
(ALCL) [18, 19]. 
Despite the promising therapeutic potential of 
ALK inhibitors, an important drawback is the rapid 
occurrence of resistance due to escape mechanisms 
including secondary mutations or activation of other 
kinase signaling pathways [17, 20–30]. A better 
understanding of the downstream ALK signaling cascades 
can inspire the development of more rationally designed 
combinatorial treatment approaches. In a previous study, 
ALK downstream signaling was characterized by in depth 
transcriptome analysis of neuroblastoma cells treated for 
six hours with the ALK inhibitor TAE684, resulting in the 
77-gene ALK signature and the identification of a negative 
MAPK feedback loop and of RET as ALK activated target 
gene [31]. Moreover, we generated transcriptome data 
between 10 minutes and 6 hours after pharmacological 
ALK inhibition to show that our established 77-gene 
signature is gradually decreasing starting from 2 hours 
after the treatment. Here, we further explore this dynamic 
transcriptome data generated upon treatment with the 
ALK inhibitor TAE684 in order to look in more detail 
into the dynamics of early transcriptional responses 
following ALK inhibition to improve our understanding 
on downstream ALK signaling and identify novel targets 
for combination therapy. To this end, we performed 
differential gene expression analysis at different time 
points following TAE684 treatment of the neuroblastoma 
cell line CLB-GA with an activating ALKR1275Q mutation.
RESULTS AND DISCUSSION
MAPK, PI3K, RET and MYC(N) signaling 
pathways are downregulated starting from 1 to 2 
hours after TAE684 treatment
In order to gain more insights into the early 
dynamics of transcriptional changes after pharmacological 
inhibition of ALK signaling in neuroblastoma cells, the 
neuroblastoma cell line CLB-GA, which harbours an 
ALKR1275Q mutation, was treated with the ALK inhibitor 
TAE684 and DMSO as control. While TAE684 did not go 
into clinical trials, TAE684 is a valid ALK-inhibitor as we 
previously showed that the transcriptional responses for 
this drug and the more clinically relevant ones, such as 
crizotinib, LDK378 and X396, are very similar [31]. RNA 
expression profiling was performed on cells harvested 
10 and 30 minutes, 1, 2, 4 and 6 hours after treatment 
(Supplementary Figure 1).
Our previously established 77-gene ALK signature 
[31] significantly decreases from 2 hours after ALK 
inhibitor treatment, as shown earlier by Lambertz et al. 
[31]. In this study, we evaluated the dynamic regulation of 
known ALK downstream pathways, i.e. MAPK, PI3K, RET 
and MYC/MYCN signaling pathways [4–7, 31–34], by 
calculating signature activity scores for drugs specifically 
blocking these pathways. These drug signature scores 
summarize the transcriptional response of the components 
of a given signaling pathway upon pharmacological 
pathway inhibition. Our data confirm ALK regulation of 
these pathways and furthermore show that MAPK, PI3K and 
RET pathway activity is decreased as early as 1 to 2 hours 
after the start of TAE684 treatment, as the corresponding 
inhibitor scores become activated at those time points 
(Figure 1A–1C; Supplementary Figures 2A–2C, 3A–3C). 
Furthermore, we observed that MYCN expression levels 
significantly drop 1 hour after the treatment (p = 0.0015) 
(Figure 1D; Supplementary Figure 2D). As expected, 
MYC(N) activity scores [35, 36] follow a delayed response 
at later time points (Figure 1E, 1F; Supplementary Figures 
2E, 2F, 3D, 3E). These results are in line with the previously 
established regulatory role on MYCN transcription initiation 
for ALK, in addition to its effect on MYCN activity via 
phosphorylation [32, 34, 37–39]. 
To identify other dynamically regulated pathways 
upon ALK inhibition, functional enrichment analysis 
was performed on a set of k-means clusters of genes with 
similar transcriptional responses over the timeframe. 
After k-means clustering with 9 centers, as defined by 
the elbow method, we combined clusters with similar 
expression patterns over time yielding a total of 6 different 
clusters (Figure 2A; Supplementary Figures 4A, 4B, 
5A). Moreover, 4 of these clusters, namely cluster A, 
B, D and E, are showing a clear dynamic pattern, with 
a change in expression starting at 120 or 240 minutes 
and increasing over time, while the other 2 are showing a 
more modest pattern over time with only a small change 
at the latest time point (Figure 2A, Supplementary Figure 
5A). Functional characterization of these 4 clusters 
through evaluating the enrichment for gene ontology 
terms (MSigDB ‘c5 Gene Ontology (GO) Biological 
Process Ontology (BP) v6.0’), oncogenic signatures 
(MSigDB ‘c6 Oncogenic Signatures v5.0’) and pathways 
of the Reactome Database [40, 41] confirmed that these 
clusters consist of MYC, MAPK or mTOR targets and are 
involved in regulation of the MAPK cascade, in keeping 
with the downregulation of the MYC(N), PI3K-AKT-
mTOR and MAPK pathway (Figure 2B; Supplementary 
Figure 5B, 5C). Moreover, cluster E is also enriched 
for genesets linked to epigenetic processes, regulating 
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amongst others chromatin structure and gene expression 
(Figure 2B; Supplementary Figures 5B, 5C). 
Taken together, this analysis provides insights into 
the dynamics of inactivation of ALK driven downstream 
pathways in ALK mutant neuroblastoma cells upon ALK 
inhibition and validates the applicability of the presented 
dataset to further scrutinize early temporal effects of ALK 
inhibition.
Figure 1: Signature score analysis for MAPK, PI3K, RET and MYC(N) signaling pathways, downregulated starting 
from 1 or 2 hours after TAE684 treatment. (A–E) MEK inhibitor (trametinib) (A), PI3K/mTOR inhibitor (BEZ-235) (B) and RET 
inhibitor (vandetanib) (C) signatures are upregulated from 1 or 2 hours after treatment of the CLB-GA cell line with 320 nM TAE684, while 
MYCN mRNA expression levels (D) are downregulated from 1 hour after treatment and the MYCN activity score from Valentijn et al. [35] 
(E) and the MYC signature score from Fredlund et al. [36] (F) from respectively 2 and 4 hours after pharmacological ALK blockade. Log2 
transformed ratios of expression levels of TAE684 treated vs DMSO control samples are plotted. 
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Figure 2: Functional characterization of the genes in the clusters with the MSigDB ‘c5 Gene Ontology (GO) Biological 
Process Ontology (BP) v6.0’. (A) The cluster plots represent the dynamic pattern of the expression of the genes belonging to 1 of the 
6 clusters. The mean of the ratio of the expression in the TAE684 vs DMSO treated sample is plotted for each gene. The red lines show the 
average dynamic pattern of the expression of the genes belonging to these clusters, calculated by the average of the mean of the ratio of the 
expression in the TAE684 vs DMSO treated sample. (B) Plot showing the MSigDB ‘c5 Gene Ontology (GO) Biological Process Ontology 
(BP) v6.0’ genesets that are enriched in at least one of the four clusters, which are showing a clear dynamic pattern (clusters A, B, D, E). 
The size of each node corresponds to the number of genes overlapping between the cluster and the gene set and the colour represents the 
adjusted p-value of the enrichment test. Green stars indicate the genesets related to the MYC(N), KRAS-MAPK, PI3K/mTOR pathways.
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MYC(N) signaling is upregulated immediately 
following ALK inhibition 
To functionally scrutinize the transcriptional 
changes upon ALK inhibitor treatment, Gene Set 
Enrichment Analysis (GSEA [42]) was performed 
using the ‘Hallmarks v5.0’ genesets from the Molecular 
Signatures Database (MSigDB) (software.broadinstitute.
org/gsea/msigdb) at the different time points. This analysis 
further validates that the signaling pathways KRAS 
(MAPK) and PI3K-mTOR are significantly repressed 
(Figure 3A). Remarkably, one of the MYC genesets 
(HALLMARK_MYC_TARGETS_1) is significantly 
enriched for genes upregulated 30 minutes after treatment 
and significantly enriched for genes downregulated 6 
hours after pharmacological ALK blockade (Figure 3A, 
indicated in red). Moreover, we observed a significant 
increase in the Fredlund MYC signature [36] 2 hours after 
ALK inhibition (p = 0.0038) (Figure 1F, Supplementary 
Figure 2F). Therefore, we also performed GSEA on other 
MYC(N) activity signatures and confirmed for 4 other 
genesets an initial upregulation (at 10 or 30 minutes after 
ALK inhibitor treatment) followed by a downregulation 
(from 2 hours after ALK inhibitor treatment) (Figure 
3B). The observation of this initial upregulation of 
MYCN activity scores is intriguing and needs further 
investigation. 
Adrenomedullin (ADM) is the earliest 
upregulated gene upon pharmacological ALK 
inhibition of NB cells
In order to identify the set of early and late genes 
that significantly change transcriptionally, differential gene 
expression analysis comparing TAE684 treated cells with 
DMSO treated controls was performed at each time point. 
This analysis revealed that no significant transcriptional 
changes occur as early as 10 or 30 minutes after treatment 
(using adjusted p-value (False Discovery Rate (FDR)) 
< 0.05), while starting from 2 hours after treatment 
an increasing number of significantly, differentially 
expressed genes are identified (Supplementary Table 1). 
Our observations are in line with these from Lai et al. [43], 
who have shown that transcriptional events occur between 
2 and 4 hours after inhibition of a receptor tyrosine kinase. 
Interestingly, one gene showed significant 
differential upregulation 1 hour post-TAE684 treatment, 
i.e. adrenomedullin (ADM) (Figure 4A; Supplementary 
Figure 6A). Interestingly, using second- and third-
generation ALK inhibitors [31], the upregulation of ADM 
upon ALK inhibition was confirmed in CLB-GA and 
Kelly (Supplementary Figure 6B, 6C). Moreover, we 
could validate ADM upregulation 6 hours after treatment 
with TAE684 in more NB cell lines with an ALK 
amplification, an ALKR1275Q or ALKF1174L mutation (Figure 
4B). Furthermore, the early upregulation of ADM was 
validated in the cell line NB-1 upon pharmacological ALK 
inhibition with TAE684 (Figure 4C), as the increase was 
already detectable 1 hour after the treatment. In addition, 
ADM expression levels are also significantly induced in 
the CLB-GA cell line, following PI3K/mTOR inhibitor 
BEZ-235, MEK antagonist trametinib and RET repressor 
vandetanib treatment [31] (Supplementary Figure 6D). 
Interestingly, ADM upregulation was also observed in the 
Anaplastic Large Cell Lymphoma (ALCL) cell line TS 
treated with three different ALK inhibitors for 6 hours [44] 
(Figure 4D).
Adrenomedullin is upregulated under hypoxic 
conditions in neuroblastoma
As ADM is known to be induced under hypoxia [45–
51], we investigated publically available transcriptome 
data from hypoxic versus normoxic neuroblastoma 
cells [52] and confirmed ADM upregulation under 
hypoxic conditions in these cells (Figure 4E). Of further 
interest, ADM is higher expressed in more aggressive 
neuroblastoma tumours (stage 4 versus other stages) 
(Figure 4F). 
Furthermore, the observed ADM upregulation is 
intriguing and has a potentially important translational 
consequence. In addition to ADM activation upon hypoxia 
[45–51], ADM was also shown to act as growth factor, 
prevent apoptosis-mediated cell death, increase tumour 
cell motility and metastasis and induce angiogenesis 
in various cancer types [47–49, 51, 53–59]. Of further 
importance, it has been reported that hypoxia, which 
can activate ADM [45–51], induces resistance to ALK 
inhibitors in non-small cell lung cancer [60] and that ADM 
expression levels are increased in tyrosine kinase inhibitor 
sunitinib resistant renal cell carcinoma [61]. In view of 
these observations, we evaluated whether combining 
an adrenomedullin receptor antagonist (ADM22-52) 
[61] together with TAE684 would sensitize NB cells to 
ALK inhibition. No additional effects on decrease in cell 
viability were observed (data not shown). This observation 
could be due to the fact that elevated ADM levels have no 
effect on sensitivity for ALK inhibitors in neuroblastoma 
cells. Alternatively, given that the cell lines tested are 
very sensitive to the inhibitor with immediate strong 
and massive apoptotic effects, under these conditions 
elevated ADM levels may have no immediate effects 
on cell viability, while in a later stage in cells rendered 
resistant to ALK inhibition, combined exposure to both 
ALK inhibition and the ADM inhibitor might have effect.
MATERIALS AND METHODS
CLB-GA time series dataset
The CLB-GA time series dataset has been 
described before [31]. The neuroblastoma CLB-GA cell 
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Figure 3: Gene Set Enrichment Analysis (GSEA) with the hallmarks and the MYC(N) signaling genesets shows that 
MYC(N) signaling is upregulated immediately following ALK inhibition. (A and B) Heatmap showing the genesets of the 
‘Hallmarks v5.0’ genesets from MSigDB (A) and an in house compiled gene set collection containing all MYC target genesets from this 
hallmark catalogue as well as publically available MYC(N) activity or target signatures [35, 60–66] (B), that are enriched among the genes 
upregulated after ALK inhibition (positively enriched) (red) or that are enriched among the genes downregulated after ALK inhibition 
(negatively enriched) (blue) according to GSEA (with FDR < 0.1) [41]. Indicated in red are the genesets that are upregulated at earlier and 
downregulated at the later time points following ALK inhibition. Green stars indicate the genesets related to the MYC(N), KRAS-MAPK, 
PI3K/mTOR pathways.
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Figure 4: Adrenomedullin (ADM) is the earliest upregulated gene upon pharmacological ALK inhibition of NB cells. (A) 
ADM mRNA is significantly upregulated starting from 1 hour after TAE684 treatment of the CLB-GA cell line. Ratios of log2 transformed 
expression levels of TAE684 treated vs DMSO control samples are plotted. (B) ADM mRNA expression levels shown in several ALK wild 
type (NGP, SK-N-AS, IMR-32) and ALK mutant (NB-1, CLB-GA, LAN-5, UKF-NB3, SMS-KCNR, Kelly, SK-N-SH) cell lines treated 
for 6 hours with 0.32 μM TAE684 or DMSO. (C)ADM mRNA expression levels are upregulated in NB cell line NB-1 (ALKamp) 1 hour and 
6 hours after treatment with 0.32 μM TAE684 compared to the DMSO control. (D) ADM expression levels are upregulated 6 hours upon 
ALK inhibition with three different ALK inhibitors in the ALCL cell line TS. (E) ADM mRNA expression levels are upregulated in 11 NB 
cell lines under hypoxic conditions. (F) ADM expression levels are higher in stage 4 primary neuroblastoma tumours versus neuroblastoma 
tumours of stage 1, 2, 3 and 4S. Boxplots represent mean ± 95% confidence interval. Statistical analyses: unpaired one-way ANOVA with 
Bonferroni correction (B. & C. & D.), paired t-test (E.) and unpaired t-test (F.). *P < 0.05, **P < 0.01, ***P < 0.001. 
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line (ALKR1275Q) was cultured in RPMI-1640 medium 
(Invitrogen), supplemented with fetal bovine serum 
(10%), kanamycin (100 μg/ml) penicillin/streptomycin 
(100 IU/ml), L-glutamine (2 mM) and HEPES (25 mM) 
(Life Technologies), and maintained at 37°C in a 5% C02-
humidified environment. At different time points (10, 30 
minutes, 1, 2, 4 and 6 hours) after treatment with 0.32 
μM of the small molecule ALK inhibitor NVP-TAE684 
(hereafter TAE684) (SelleckChem, S1108) or DMSO 
(VWR) as solvent control, cells were harvested and 
RNA quality was analysed using Experion (Bio-Rad) 
prior to gene-expression profiling. Samples were labelled 
and hybridized to the Sureprint G3 human GE 8x60K 
microarrays (Agilent Technologies), according to the 
manufacturer’s guidelines and starting from 200 ng RNA. 
The data was normalized with the vsn method in R version 
3.3.3 (packages vsn and limma). The R package BioMart 
was used to annotate gene names to their corresponding 
probes. Probes detecting at least a two-fold higher 
expression than the negative control probes of the array in 
at least 60% of the DMSO or TAE samples, were selected 
as background correction. Data can be accessed through 
ArrayExpress (accession number E-MTAB-3206) [31].
Signature score analysis
To establish MAPK, PI3K/mTOR and RET inhibitor 
signatures, we used published gene expression profiling 
data (ArrayExpress accession number E-MTAB-3206) 
[31]. This dataset contains expression profiling data of 
the CLB-GA cell line 6 hours after treatment with MAPK 
inhibitor trametinib, the dual PI3K/mTOR repressor BEZ-
235 or RET antagonist vandetanib and DMSO as control. 
Using the limma R-package, differential expression 
analysis was performed comparing the DMSO-control and 
the inhibitor treated samples. The established signatures 
consist of the differentially expressed genes with adjusted 
p-value (False Discovery Rate (FDR)) < 0.05. In addition, 
a published MYCN and a published MYC signature 
were used to establish the MYC(N) pathway activity 
[35, 36]. Signatures score analysis was conducted using 
a rank-scoring algorithm as described previously [31, 36]. 
For each time point and each duplicate separately, both 
the ratio between the TAE684 treated sample and his 
corresponding control sample (Figure 1) as the absolute 
values (Supplementary Figure 2) were plotted using 
GraphPad Prism 7. 
Gene set enrichment analysis 
Gene set enrichment analysis (GSEA [42]) was 
performed using the MSigDB ‘Hallmarks v5.0’ gene sets 
(software.broadinstitute.org/gsea/msigdb) and an in house 
compiled gene set catalogue containing all MYC target 
genesets from this hallmark catalogue as well as publically 
available MYC(N) activity or target signatures [35, 36, 
62–67]. The genesets, showing positively or negatively 
enrichment at minimum one time point and with a FDR 
< 0.1 are plotted in a heatmap. Data was plotted as the 
mean of the ratio of the TAE684 treated sample and his 
corresponding control sample at every time point.
Cluster analysis and pathway enrichment 
analysis in the clusters
Using the Bayesian Information Criterion (BIC) and 
the elbow method, 9 was defined as the optimal number 
of clusters in the dataset (Supplementary Figure 4A, 4B). 
K-means clustering was performed on the expression 
level ratios of TAE684/DMSO samples for each time 
point in R (with k = 9). However, visual inspection of the 
expression patterns of the genes in the clusters showed that 
some clusters have a similar pattern over time (clusters 
1 and 2, 4 and 7, 6 and 9) (Supplementary Figure 4B) 
and were therefore merged, ending with 6 final clusters 
(Supplementary Figure 5A). For every cluster, the average 
response of the genes was plotted as a line (red line). The 
4 clusters that are showing a clear dynamic pattern over 
time, were screened for MSigDB ‘c5 Gene Ontology 
(GO) Biological Process Ontology (BP) v6.0’ (software.
broadinstitute.org/gsea/msigdb), MSigDB ‘c6 Oncogenic 
Signatures v5.0’ and overrepresented Reactome pathways 
[40, 41] using the R-packages clusterProfiler and 
Reactome Pathway Analysis [68, 69].
Differential expression analysis
At every time point, differential expression analysis 
was performed using the R package limma, comparing 
the DMSO-control and the TAE684-treated sample. 
The duplicate experiments, independently generated 
at different time points, were set as blocking factor. 
Significantly differentially expressed genes refer to those 
with an adjusted p-value (FDR) < 0.001. Results are 
shown in Supplementary Table 2.
Analysis of ADM expression levels after ALK 
inhibition using qPCR 
ADM expression levels were measured in CLB-
GA (ALKR1275Q) and Kelly (ALKF1174L) cells that were 
treated for 6 hours with DMSO as control solvent and 
0.09 μM of ALK inhibitor, PF06463922 acetate (Sigma-
Aldrich, PZ0271) (dissolved in sterile DMSO and diluted 
to the final concentration in culture medium) and in 
NB-1 (ALKamp) cells that were treated for 1 and 6 hours 
with DMSO as control solvent and 0.32 μM of TAE684 
(dissolved in sterile DMSO and diluted to the final 
concentration in culture medium).
RNA extraction, cDNA synthesis and RT-qPCR of 
these samples was performed as described earlier [31]. 
The Cq-values for ADM expression were normalized with 
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data of at least two reference genes (TBP, YWHAZ, B2M, 
HPRT1 and SDHA) (primer sequences: Supplementary 
Table 2) using qBasePlus software (Biogazelle).
Evaluation of ADM expression in public mRNA 
expression datasets
ADM expression levels were evaluated in (1) 
CLB-GA cells treated with 0.2 μM LDK378, 0.32 μM 
TAE684, 0.06 μM X396, 0.5 μM crizotinib, 0.05 μM 
trametinib (MEK-inhibitor), 0.5 μM BEZ-235 (dual PI3K/
mTOR inhibitor) and 9.5 μM vandetanib for 6 hours 
(ArrayExpress accession number E-MTAB-3206) [31], (2) 
10 NB cell lines treated with 0.32 μM TAE684 for 6 hours 
(ArrayExpress accession number E-MTAB-3205) [31], (3) 
the ALCL TS cell line treated with three different ALK 
inhibitors for 6 hours (GEO accession number GSE6184) 
[44], (4) 11 NB cell lines that were cultured under 
normoxic and hypoxic conditions (1% O2 instead of 20%) 
for 18 hours (GEO accession number GSE17714) [52] and 
(5) a cohort of 283 neuroblastoma tumour samples (GEO 
accession number GSE85047). 
Statistical analyses
Statistical significance was calculated with 
GraphPad Prism7 by unpaired one-way ANOVA with 
Bonferroni correction when comparing more than two 
unmatched groups, while (un)-paired t-test was chosen 
when comparing two groups.
CONCLUSIONS
In summary, dynamic expression profiling following 
ALK inhibition of ALK mutated neuroblastoma cells 
revealed (1) unexpected early ADM upregulation with 
potential implications for design of more effective ALK 
targeted therapy, (2) an initial increase of MYC(N) activity 
immediately after ALK inhibition and (3) confirmed 
inhibition after 1 to 2 hours of the ALK downstream 
MAPK, PI3K-AKT, RET and MYC(N) pathways. 
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